

# SPECIALTY GUIDELINE MANAGEMENT

## EYLEA (aflibercept) EYLEA HD (aflibercept)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Eylea is indicated for the treatment of:

- A. Diabetic macular edema
- B. Diabetic retinopathy
- C. Neovascular (wet) age-related macular degeneration
- D. Macular edema following retinal vein occlusion
- E. Retinopathy of Prematurity

Eylea HD is indicated for the treatment of:

- A. Diabetic macular edema
- B. Diabetic retinopathy
- C. Neovascular (wet) age-related macular degeneration

All other indications are considered experimental/investigational and not medically necessary.

#### II. CRITERIA FOR INITIAL APPROVAL

##### **A. Diabetic Macular Edema**

Authorization of 6 months may be granted for treatment of diabetic macular edema.

##### **B. Diabetic Retinopathy**

Authorization of 6 months may be granted for treatment of diabetic retinopathy.

##### **C. Neovascular (Wet) Age-Related Macular Degeneration**

Authorization of 6 months may be granted for treatment of neovascular (wet) age-related macular degeneration.

##### **D. Macular Edema Following Retinal Vein Occlusion**

Authorization of 6 months may be granted for treatment of macular edema following retinal vein occlusion.

##### **E. Retinopathy of Prematurity**

Authorization of 6 months may be granted for treatment of retinopathy of prematurity.

#### III. CONTINUATION OF THERAPY

<b>Reference number(s)</b>
2024-A

Authorization of 12 months may be granted for continued treatment of an indication listed in Section II for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

#### IV. REFERENCES

1. Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; February 2023.
2. Eylea HD [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; August 2023.
3. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>.
4. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp>.
5. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Retinal Vein Occlusions. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp>.